Australia Research Shows Male Bias In 300 Percent Increase In Ritalin
This article was originally published in PharmAsia News
Australian authorities report a 300 percent increase in the use of Novartis's Ritalin (methylphenidate) over the past seven years, most for treating boys
You may also be interested in...
Circassia is returning the US rights to two COPD drugs to AstraZeneca as it admits it cannot meet its debt payments from the deal.
At their second meeting on COVID-19, drug regulators from around the world have stressed the importance of large, multi-arm studies in generating the data needed for the approval of potential coronavirus therapies. The European Medicines Agency, which organized the meeting, has also announced a new coronavirus task force to identify promising drug candidates and help steer them through development to regulatory approval.